Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia
PACTR201904797961340Phase 3Completed
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of valganciclovir in cytomegalovirus disease (CMV), Tuberculosis (TB), pneumonia and 1 more, sponsored by Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa. Primary endpoint: Mortality. Started Feb 2020; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)Tuberculosis (TB)pneumoniahuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR201904797961340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201904797961340.